Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza
Article Abstract:
A chemical that inhibits the enzyme neuraminidase in the influenza virus may protect against the disease and reduce symptoms in those who have it. Neuraminidase is important in viral reproduction and probably allows the virus to penetrate respiratory epithelial cells. Four studies tested the chemical GG167 on 160 people to see if the chemical could prevent influenza or reduce its symptoms. Some studies gave GG167 nose drops to the volunteers four hours before they were experimentally infected with the influenza A virus and some gave the GG167 drops 1 to 2 hours after infection. Altogether, 112 got the GG167 drops and 48 volunteers got a placebo. GG167 significantly reduced viral shedding and the incidence of influenza in those who received it prophylactically. It also significantly reduced symptoms in those who received it after developing influenza. There were no significant side effects.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: A randomized controlled trial
Article Abstract:
The dose-related safety, immunogenicity, and protective efficacy of an experimental trivalent influenza virus hemagglutinin (rHAO) vaccine produced in insect cells were determined using recombinant baculoviruses. The findings suggested that it is possible to generate a substantial amount of protection in an immunologically primed population against influenza with a pure hemagglutinin vaccine, even in the presence of significant antigenic drift.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial
Article Abstract:
A double-blind, randomized controlled trial was conducted to compare the vaccination success rate and the reaction profile of various Aventis Pasteur smallpox vaccine (APSV). ASPV was found as an effective vaccine even at diluted doses allowing for expansion of the current stockpile while, reactogenicity was found not reduced with dilution of the vaccine and as with other smallpox vaccine may impair daily activities.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Acute and chronic chorioamnionitis and the risk of perinatal human immunodeficiency virus-1 transmission. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: Feasibility and early outcomes: Feasibility and early outcomes
- Abstracts: Anatomy and function of the skin: Part 3-dermis and adjacent structures. Development of a district-wide teledermatology service
- Abstracts: Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: Meta-analysis of randomized trials
- Abstracts: The anesthetic efficacy of articaine in buccal infiltration of mandibular posterior teeth. Anesthetic efficacy of the palatal-anterior superior alveolar injection
- Abstracts: Role of the breast care nurse specialist in a diagnostic clinic. The development and audit of a nurse-led urology/oncology clinic